> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sarepta Duchenne Drug Approval Gains Voucher
- URL: https://www.fdaweb.com/sarepta-duchenne-drug-approval-gains-voucher/
- Published: 2016-10-17T12:00:00.000Z
- Updated: 2026-09-14T21:39:47.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5137084

*Federal Register* Notice: FDA has issued a priority review voucher to Sarepta Therapeutics after determining its NDA for Duchenne muscular dystrophy drug Exondys 51 (eteplirsen) met criteria as a rare pediatric disease product. To view this notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2016-10-17/pdf/2016-24947.pdf?ref=fdaweb.com).